Loading...
Loading...
DCPH| Name | Value |
|---|---|
| Revenues | 43.3M |
| Cost of Revenue | 1.3M |
| Gross Profit | 42.0M |
| Operating Expense | 95.7M |
| Operating I/L | -53.7M |
| Other Income/Expense | 4.1M |
| Interest Income | 4.1M |
| Pretax | -49.6M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -49.6M |
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing drugs to combat drug resistance in cancer therapies. Its lead drug candidate, QINLOCK, is used for treating gastrointestinal stromal tumors (GIST) and is being studied for second-line GIST treatment. The company is also developing vimseltinib, a potent inhibitor for tenosynovial giant cell tumor (TGCT), and DCC-3116 for RAS/RAF mutant cancers in preclinical stages.
